ClinicalTrials.gg
CompletedNCT01458587Updated Mar 14, 2013Results posted

Levulan PDT Versus Vehicle for Extremity Actinic Keratoses (AK)

A Phase 2 interventional study of Aminolevulinic Acid PDT (ALA) and Vehicle PDT (VEH) in Keratosis, Actinic, sponsored by DUSA Pharmaceuticals, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-03-14.

Sponsored by DUSA Pharmaceuticals, Inc. (part of Sun Pharmaceutical Industries Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic — 1 open to participants now, 2 under way, none of them phase 3. Aminolevulinic Acid · Keratosis, Actinic.

Enrollment
12th of 29
70 · median 32
Started
2011
with 1 other
Phase 2
11 of 29
none open now
Registered
4th of 29
by date
Lead sponsor
9 of 29
DUSA Pharmaceuticals, Inc.

Among the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, this one is the 12th largest by enrollment, is one of 2 that started in 2011, is one of 11 in phase 2, and was the 4th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

1 of the 29 studies testing Aminolevulinic Acid in Keratosis, Actinic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Aminolevulinic Acid

Aminolevulinic Acid: first FDA approval 1999 (LEVULAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing Aminolevulinic Acid in Keratosis, Actinic, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Levulan PDT is safe and effective in the treatment of actinic keratoses on the upper arms and hands.

03

Conditions studied

  • Keratosis, Actinic

Browse trials for

Keywords

  • Actinic keratosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 4 Grade 1/2 AKs on each upper extremity

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • history of cutaneous photosensitization, porphyria, to porphyrins or photodermatosis
  • lesions suspicious for skin cancer (skin cancer not ruled out by ) or untreated skin cancers within the Treatment Area
  • skin pathology or condition which could interfere with the evaluation of the test product or requires the use of interfering topical or systemic therapy
  • Subject is
  • unsuccessful outcome from previous ALA-PDT therapy
  • currently enrolled in an drug or device study
  • has received an investigational drug or been treated with an investigational device within 30 days prior to the initiation of treatment
  • known sensitivity to one or more of the vehicle components (ethyl alcohol, isopropyl alcohol, laureth 4, polyethylene glycol)
  • use of the following topical preparations on the extremities to be treated:

    • Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g.glycolic acid, lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of initiation of treatment.
    • Cryotherapy within 2 weeks of initiation of treatment
    • Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of initiation of treatment.
    • Microdermabrasion, laser ablative treatments, ALA-PDT, chemical peels, 5-FU, diclofenac, imiquimod or other topical treatments for AK within 8 weeks of initiation of treatment.
    • Two or more ALA PDT treatments in the past 6 months
  • use of systemic retinoid therapy within 6 months of initiation of treatment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    ALA

    Drug: Aminolevulinic Acid PDT (ALA)

  • Placebo comparator
    Vehicle

    Drug: Vehicle PDT (VEH)

Interventions

  • 20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light

    Also known as: Levulan Kerastick

  • DrugVehicle PDT (VEH)

    Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light

06

What researchers measure

Primary outcomes

  1. Lesion Clearance Rate

    Clearance rate for all lesions

    Time frame: Week 12

Secondary outcomes

  1. Lesion Clearance Rate

    Time frame: Week 8

  2. Complete Clearance Rate

    proportion of subjects with a count of zero lesions in the treatment area

    Time frame: Week 8

  3. Complete Clearance Rate

    proportion of subjects with a count of zero lesions in the treatment area

    Time frame: Week 12

  4. Partial Clearance Rate

    proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

    Time frame: Baseline and Week 8

  5. Partial Clearance Rate

    proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

    Time frame: Baseline and Week 12

  6. Subject Satisfaction Score

    Subject satisfaction score 1. = Excellent (very satisfied) 2. = Good (moderately satisfied) 3. = Fair (slightly satisfied) 4. = Poor (not satisfied at all)

    Time frame: Week 12

  7. Hyperpigmentation at Baseline

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: Baseline

  8. Hyperpigmentation at Visit 3

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: 2 weeks after PDT #1

  9. Hyperpigmentation at Visit 4

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: 8 weeks after PDT #1

  10. Hyperpigmentation at Visit 5

    HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

    Time frame: 12 weeks after PDT #1

  11. Hypopigmentation at Baseline

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

    Time frame: Baseline

  12. Hypopigmentation at Visit 3

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

    Time frame: 2 Weeks after PDT #1

  13. Hypopigmentation at Visit 4

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

    Time frame: 8 Weeks after PDT #1

  14. Hypopigmentation at Visit 5

    HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

    Time frame: 12 Weeks after PDT #1

  15. Erythema at Baseline

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: Baseline

  16. Erythema Post-Light Treatment

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 5 Minutes after PDT #1

  17. Erythema at Visit 3

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 2 Weeks after PDT #1

  18. Erythema at Visit 4

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 8 Weeks after PDT #1

  19. Erythema at Visit 5

    Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

    Time frame: 12 Weeks after PDT #1

  20. Edema at Baseline

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: Baseline

  21. Edema Post-Light Treatment

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 5 Minutes after PDT #1

  22. Edema at Visit 3

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 2 Weeks after PDT #1

  23. Edema at Visit 4

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 8 Weeks after PDT #1

  24. Edema at Visit 5

    EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

    Time frame: 12 Weeks after PDT #1

  25. Stinging/Burning at Baseline

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: Baseline

  26. Stinging/Burning During Light Treatment

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: During PDT #1

  27. Stinging/Burning Post Light Treatment

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 5 minutes after PDT #1

  28. Stinging/Burning at Visit 3

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 2 Weeks after PDT #1

  29. Stinging/Burning at Visit 4

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 8 Weeks after PDT #1

  30. Stinging/Burning at Visit 5

    STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

    Time frame: 12 Weeks after PDT #1

  31. Scaling and Dryness at Baseline

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: Baseline

  32. Scaling and Dryness at Visit 3

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: 2 Weeks Post PDT #1

  33. Scaling and Dryness at Visit 4

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: 8 Weeks Post PDT #1

  34. Scaling and Dryness at Visit 5

    SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

    Time frame: 12 Weeks Post PDT #1

  35. OOZING/VESICULATION/CRUSTING at Baseline

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: Baseline

  36. OOZING/VESICULATION/CRUSTING at Visit 3

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: Week 2 after PDT #1

  37. OOZING/VESICULATION/CRUSTING at Visit 4

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: 8 Weeks after PDT #1

  38. OOZING/VESICULATION/CRUSTING at Visit 5

    OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

    Time frame: 12 Weeks after PDT #1

07

Results

Posted Feb 4, 2013

Participant flow

Recruitment period was from 28November2011 - 4April2012 at 3 medical clinics in the U.S.

Participant flow — Overall Study
MilestoneAminolevulinic AcidVehicle
Started3535
Completed3435
Not completed10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryLesion Clearance Rate

Clearance rate for all lesions

Time frame:
Week 12
Reported as:
Median · percentage of lesions cleared
Lesion Clearance Rate
percentage of lesions clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Lesion Clearance Rate88.7 ± 25.170.0 ± 31.116.7 ± 27.65.6 ± 26.8
SecondaryLesion Clearance Rate
Time frame:
Week 8
Reported as:
Median · percentage of lesions cleared
Lesion Clearance Rate
percentage of lesions clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Lesion Clearance Rate75.0 ± 34.647.4 ± 30.73.3 ± 28.76.3 ± 25.8
SecondaryComplete Clearance Rate

proportion of subjects with a count of zero lesions in the treatment area

Time frame:
Week 8
Reported as:
Number · arms 100% cleared
Complete Clearance Rate
arms 100% clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Complete Clearance Rate8400
SecondaryComplete Clearance Rate

proportion of subjects with a count of zero lesions in the treatment area

Time frame:
Week 12
Reported as:
Number · arms 100% cleared
Complete Clearance Rate
arms 100% clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Complete Clearance Rate12701
SecondaryPartial Clearance Rate

proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

Time frame:
Baseline and Week 8
Reported as:
Number · arms >75% cleared
Partial Clearance Rate
arms >75% clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Partial Clearance Rate18512
SecondaryPartial Clearance Rate

proportion of subjects with 75% or more reduction in the AK count in the Treatment Area as compared to baseline.

Time frame:
Baseline and Week 12
Reported as:
Number · arms >75% cleared
Partial Clearance Rate
arms >75% clearedALA+OCCALA-OCCVEH+OCCVEH-OCC
Partial Clearance Rate211532
SecondarySubject Satisfaction Score

Subject satisfaction score 1. = Excellent (very satisfied) 2. = Good (moderately satisfied) 3. = Fair (slightly satisfied) 4. = Poor (not satisfied at all)

Time frame:
Week 12
Reported as:
Number · participants
Subject Satisfaction Score
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Very satisfied13731
Moderately satisfied161455
Slightly satisfied3879
Not satisfied362020
SecondaryHyperpigmentation at Baseline

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
Baseline
Reported as:
Number · participants
Hyperpigmentation at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)5511
Grade 1 (light)20192323
Grade 2 (moderate - small)91088
Grade 3 (moderate - moderate)1133
SecondaryHyperpigmentation at Visit 3

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
2 weeks after PDT #1
Reported as:
Number · participants
Hyperpigmentation at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)4411
Grade 1 (light)19202121
Grade 2 (moderate - small)9101010
Grade 3 (moderate - moderate)2133
SecondaryHyperpigmentation at Visit 4

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
8 weeks after PDT #1
Reported as:
Number · participants
Hyperpigmentation at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)2200
Grade 1 (light)24211917
Grade 2 (moderate - small)8111113
Grade 3 (moderate - moderate)1144
SecondaryHyperpigmentation at Visit 5

HYPERPIGMENTATION SCALE Grade 0 = No hyperpigmentation Grade 1 = Light hyperpigmentation involving small areas Grade 2 = Moderate hyperpigmentation involving small areas; light hyperpigmentation involving moderate areas Grade 3 = Moderate hyperpigmentation involving moderate sized areas; light hyperpigmentation involving large areas; small areas of marked hyperpigmentation Grade 4 = Marked hyperpigmentation involving moderate or large sized areas

Time frame:
12 weeks after PDT #1
Reported as:
Number · participants
Hyperpigmentation at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)2200
Grade 1 (light)25232020
Grade 2 (moderate - small)681111
Grade 3 (moderate - moderate)0044
SecondaryHypopigmentation at Baseline

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Time frame:
Baseline
Reported as:
Number · participants
Hypopigmentation at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)9988
Grade 1 (light)21212424
Grade 2 (moderate - small)5522
Grade 3 (moderate - moderate)0011
SecondaryHypopigmentation at Visit 3

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Time frame:
2 Weeks after PDT #1
Reported as:
Number · participants
Hypopigmentation at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)101077
Grade 1 (light)20202626
Grade 2 (moderate - small)4511
Grade 3 (moderate - moderate)0011
SecondaryHypopigmentation at Visit 4

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Time frame:
8 Weeks after PDT #1
Reported as:
Number · participants
Hypopigmentation at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)131099
Grade 1 (light)18212323
Grade 2 (moderate - small)3411
Grade 3 (moderate - moderate)1011
SecondaryHypopigmentation at Visit 5

HYPOPIGMENTATION SCALE Grade 0 = No hypopigmentation Grade 1 = Light hypopigmentation involving small areas Grade 2 = Moderate hypopigmentation involving small areas; light hypopigmentation involving moderate areas Grade 3 = Moderate hypopigmentation involving moderate sized areas; light hypopigmentation involving large areas; small areas of marked hypopigmentation

Time frame:
12 Weeks after PDT #1
Reported as:
Number · participants
Hypopigmentation at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)1081211
Grade 1 (light)22242122
Grade 2 (moderate - small)1111
Grade 3 (moderate - moderate)0011
SecondaryErythema at Baseline

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
Baseline
Reported as:
Number · participants
Erythema at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)10101212
Grade 1 (minimal)16161312
Grade 2 (mild)89910
Grade 3 (moderate)1011
Grade 4 (severe)0000
SecondaryErythema Post-Light Treatment

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
5 Minutes after PDT #1
Reported as:
Number · participants
Erythema Post-Light Treatment
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)0044
Grade 1 (minimal)041115
Grade 2 (mild)7191713
Grade 3 (moderate)211033
Grade 4 (severe)7200
SecondaryErythema at Visit 3

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
2 Weeks after PDT #1
Reported as:
Number · participants
Erythema at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)041010
Grade 1 (minimal)8141514
Grade 2 (mild)1415910
Grade 3 (moderate)12211
Grade 4 (severe)1000
SecondaryErythema at Visit 4

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
8 Weeks after PDT #1
Reported as:
Number · participants
Erythema at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)761011
Grade 1 (minimal)17201615
Grade 2 (mild)9977
Grade 3 (moderate)2011
Grade 4 (severe)0000
SecondaryErythema at Visit 5

Erythema Scale - Grade 0 = None Grade 1 = Minimal - barely perceptible erythema Grade 2 = Mild - predominantly minimal erythema (pink) in the treated area with or without a few isolated areas of more intense erythema Grade 3 = Moderate - predominantly moderate erythema (red) in the treated area with or without a few isolated areas of intense erythema (bright red) Grade 4 = Severe - predominantly intense erythema (bright red) in the treated area with or without a few isolated areas of very intense (fiery red) erythema

Time frame:
12 Weeks after PDT #1
Reported as:
Number · participants
Erythema at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)971112
Grade 1 (minimal)7121414
Grade 2 (mild)1614109
Grade 3 (moderate)1000
Grade 4 (severe)0000
SecondaryEdema at Baseline

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
Baseline
Reported as:
Number · participants
Edema at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353535
Grade 1 (minimal)0000
Grade 2 (mild)0000
SecondaryEdema Post-Light Treatment

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
5 Minutes after PDT #1
Reported as:
Number · participants
Edema Post-Light Treatment
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)28333434
Grade 1 (minimal)5211
Grade 2 (mild)2000
SecondaryEdema at Visit 3

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
2 Weeks after PDT #1
Reported as:
Number · participants
Edema at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)27343535
Grade 1 (minimal)5100
Grade 2 (mild)3000
SecondaryEdema at Visit 4

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
8 Weeks after PDT #1
Reported as:
Number · participants
Edema at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353434
Grade 1 (minimal)0000
Grade 2 (mild)0000
SecondaryEdema at Visit 5

EDEMA SCALE Grade 0 = None Grade 1 = Minimal - scant, rare edema Grade 2 = Mild - easily seen edema, minimally palpable, involving up to 1/3 of the treatment area Grade 3 = Moderate - easily seen edema and typically palpable, involving between 1/3 to 2/3 of the treatment area Grade 4 = Severe - easily seen edema, indurated in some areas, involving over 2/3 of the treatment area

Time frame:
12 Weeks after PDT #1
Reported as:
Number · participants
Edema at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)33333535
Grade 1 (minimal)0000
Grade 2 (mild)0000
SecondaryStinging/Burning at Baseline

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
Baseline
Reported as:
Number · participants
Stinging/Burning at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353535
Grade 1 (mild)0000
Grade 2 (moderate)0000
Grade 3 (severe)0000
SecondaryStinging/Burning During Light Treatment

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
During PDT #1
Reported as:
Number · participants
Stinging/Burning During Light Treatment
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)002929
Grade 1 (mild)52066
Grade 2 (moderate)211200
Grade 3 (severe)9300
SecondaryStinging/Burning Post Light Treatment

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
5 minutes after PDT #1
Reported as:
Number · participants
Stinging/Burning Post Light Treatment
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)023033
Grade 1 (mild)72252
Grade 2 (moderate)211000
Grade 3 (severe)7100
SecondaryStinging/Burning at Visit 3

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
2 Weeks after PDT #1
Reported as:
Number · participants
Stinging/Burning at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)31353535
Grade 1 (mild)4000
Grade 2 (moderate)0000
Grade 3 (severe)0000
SecondaryStinging/Burning at Visit 4

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
8 Weeks after PDT #1
Reported as:
Number · participants
Stinging/Burning at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353434
Grade 1 (mild)0000
Grade 2 (moderate)0000
Grade 3 (severe)0000
SecondaryStinging/Burning at Visit 5

STINGING AND BURNING SCALE Grade 0 = None Grade 1 = Minimal, barely perceptible -tolerable and little discomfort Grade 2 = Moderate - tolerable, but causes some discomfort Grade 3 = Severe - very uncomfortable or intolerable

Time frame:
12 Weeks after PDT #1
Reported as:
Number · participants
Stinging/Burning at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)33333535
Grade 1 (mild)0000
Grade 2 (moderate)0000
Grade 3 (severe)0000
SecondaryScaling and Dryness at Baseline

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
Baseline
Reported as:
Number · participants
Scaling and Dryness at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)16161717
Grade 1 (minimal)15151313
Grade 2 (mild)2244
Grade 3 (moderate)2211
Grade 4 (severe)0000
SecondaryScaling and Dryness at Visit 3

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
2 Weeks Post PDT #1
Reported as:
Number · participants
Scaling and Dryness at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)351011
Grade 1 (minimal)5172019
Grade 2 (mild)51033
Grade 3 (moderate)21322
Grade 4 (severe)1000
SecondaryScaling and Dryness at Visit 4

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
8 Weeks Post PDT #1
Reported as:
Number · participants
Scaling and Dryness at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)16171414
Grade 1 (minimal)14121414
Grade 2 (mild)4533
Grade 3 (moderate)1133
Grade 4 (severe)0000
SecondaryScaling and Dryness at Visit 5

SCALING AND DRYNESS SCALE Grade 0 = None Grade 1 = Minimal - barely perceptible desquamation Grade 2 = Mild - limited areas of fine desquamation in up to 1/3 of the treatment area Grade 3 = Moderate - fine desquamation involving 1/3 to 2/3 of the treatment area or limited areas of coarser scaling Grade 4 = Severe - coarser scaling involving more than 2/3 of the treatment area or limited areas of very coarse scaling

Time frame:
12 Weeks Post PDT #1
Reported as:
Number · participants
Scaling and Dryness at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)18171212
Grade 1 (minimal)12131717
Grade 2 (mild)2255
Grade 3 (moderate)1111
Grade 4 (severe)0000
SecondaryOOZING/VESICULATION/CRUSTING at Baseline

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
Baseline
Reported as:
Number · participants
OOZING/VESICULATION/CRUSTING at Baseline
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353535
Grade 1 (minimal)0000
Grade 2 (mild)0000
Grade 3 (moderate)0000
Grade 4 (severe)0000
SecondaryOOZING/VESICULATION/CRUSTING at Visit 3

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
Week 2 after PDT #1
Reported as:
Number · participants
OOZING/VESICULATION/CRUSTING at Visit 3
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)33343434
Grade 1 (minimal)1011
Grade 2 (mild)0100
Grade 3 (moderate)1000
00000
SecondaryOOZING/VESICULATION/CRUSTING at Visit 4

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
8 Weeks after PDT #1
Reported as:
Number · participants
OOZING/VESICULATION/CRUSTING at Visit 4
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)35353434
Grade 1 (minimal)0000
Grade 2 (mild)0000
Grade 3 (moderate)0000
00000
SecondaryOOZING/VESICULATION/CRUSTING at Visit 5

OOZING/VESICULATION/CRUSTING Grade 0 = None Grade 1 = Minimal - a single area of oozing, vesiculation or crusting 3 mm diameter or less in size Grade 2 = Mild - two to four areas of oozing, vesiculation or crusting 3 mm diameter or less in size OR a single area larger than 3 mm diameter in size Grade 3 = Moderate - more than a single area of oozing, vesiculation or crusting larger than 3 mm diameter in size or more than four areas of 3 mm diameter or less in size Grade 4 = Severe - any degree of oozing, vesiculation or crusting greater than (3) above

Time frame:
12 Weeks after PDT #1
Reported as:
Number · participants
OOZING/VESICULATION/CRUSTING at Visit 5
participantsALA+OCCALA-OCCVEH+OCCVEH-OCC
Grade 0 (none)33323535
Grade 1 (minimal)0100
Grade 2 (mild)0000
Grade 3 (moderate)0000
00000

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aminolevulinic Acid—0/35 (0%)17/35 (48.6%)
Vehicle—0/35 (0%)5/35 (14.3%)
Most frequent other events
Most frequent other events
EventAminolevulinic AcidVehicle
PainSkin and subcutaneous tissue disorders9/350/35
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/350/35
Upper respiratory tract infectionInfections and infestations2/351/35
Wound infectionInfections and infestations0/352/35
Actinic keratosisSkin and subcutaneous tissue disorders0/352/35
ItchingSkin and subcutaneous tissue disorders2/350/35
SwellingSkin and subcutaneous tissue disorders2/350/35

Baseline characteristics

Age Continuous
Age Continuous(years)Aminolevulinic AcidVehicleTotal
Mean62.1 ± 9.9665.6 ± 9.3063.8 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Aminolevulinic AcidVehicleTotal
Female131225
Male222345
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aminolevulinic AcidVehicleTotal
Hispanic or Latino000
Not Hispanic or Latino353570
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aminolevulinic AcidVehicleTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White353570
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Aminolevulinic AcidVehicleTotal
United States353570
08

Study locations

3 sites
  • Therapeutics Clinical Research
    San Diego, California 92123, United States
  • Park Avenue Dermatology, PA
    Orange Park, Florida 32073, United States
  • DermResearch, Inc
    Austin, Texas 78759, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2013, 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2011
First posted
Oct 25, 2011
Start
Nov 2011
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Feb 4, 2013
Last update
Mar 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01458587
Responsible party
Sponsor
First posted
Oct 25, 2011
Start date
Nov 2011
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Feb 4, 2013
Last update
Mar 14, 2013

Study contacts

Stuart Marcus, MD, PhD
study director · DUSA Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aminolevulinic Acid

Start the discussion